Literature DB >> 22217582

Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome.

Claire L Hirst1, Gillian Ingram, Trevor P Pickersgill, Neil P Robertson.   

Abstract

BACKGROUND: Relapse is a characteristic clinical feature of multiple sclerosis (MS) and is commonly employed as a measure of efficacy following therapeutic intervention. However, less is known about the temporal evolution of subsequent disability or factors predicting recovery.
OBJECTIVES: The objective of this study was to assess the pattern of recovery following relapse and identify factors which predict recovery and residual disability following relapse.
METHODS: A total of 226 relapses were studied prospectively in a cohort of 144 patients with standardised clinical assessments of physical disability including Expanded Disability Status Scale (EDSS), 10-m timed walk, 9-hole peg test and Multiple Sclerosis Impact Scale (MSIS-29) at 0, 2, 6 and 12 months. A total of 82 patients completed 12 months of follow up without further relapse.
RESULTS: Thirty per cent of relapses were severe (change in EDSS >2.0) of which 11% failed to recover. All measures showed significant improvement at 2 months but additional improvement was also observed in 9-hole peg test and MSIS-29 up to 12 months following initial assessment. Mean time to second relapse was 382 days. The only predictor of relapse severity in the model tested was younger age; however, increasing age and initial relapse severity were also predictors of poor outcome.
CONCLUSIONS: This study shows that the majority of improvement in physical disability following relapse occurs by 2 months but that more subtle recovery can take place over 12 months in a small sub-group of patients. These data will aid in patient counselling and will also inform the timing of therapeutic intervention and physical support.

Entities:  

Mesh:

Year:  2012        PMID: 22217582     DOI: 10.1177/1352458511433919

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  11 in total

1.  Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly.

Authors:  W Oliver Tobin; Chiara Costanzi; Yong Guo; Joseph E Parisi; Stephen D Weigand; Claudia F Lucchinetti
Journal:  Mult Scler       Date:  2016-10-19       Impact factor: 6.312

2.  Radiomic analysis of the optic nerve at the first episode of acute optic neuritis: an indicator of optic nerve pathology and a predictor of visual recovery?

Authors:  Michaela Cellina; Marta Pirovano; Matteo Ciocca; Daniele Gibelli; Chiara Floridi; Giancarlo Oliva
Journal:  Radiol Med       Date:  2021-01-03       Impact factor: 3.469

3.  MRI of acute optic neuritis (ON) at the first episode: Can we predict the visual outcome and the development of multiple sclerosis (MS)?

Authors:  Michaela Cellina; Chiara Floridi; Cristina Rosti; Marcello Orsi; Marta Panzeri; Marta Pirovano; Matteo Ciocca; Giancarlo Oliva; Daniele Gibelli
Journal:  Radiol Med       Date:  2019-08-21       Impact factor: 3.469

4.  A longitudinal model for disease progression was developed and applied to multiple sclerosis.

Authors:  Michael Lawton; Kate Tilling; Neil Robertson; Helen Tremlett; Feng Zhu; Katharine Harding; Joel Oger; Yoav Ben-Shlomo
Journal:  J Clin Epidemiol       Date:  2015-05-14       Impact factor: 6.437

5.  MRI texture heterogeneity in the optic nerve predicts visual recovery after acute optic neuritis.

Authors:  Yunyan Zhang; Luanne M Metz; James N Scott; Jessie Trufyn; Gordon H Fick; Fiona Costello
Journal:  Neuroimage Clin       Date:  2014-01-14       Impact factor: 4.881

6.  A predictive model for corticosteroid response in individual patients with MS relapses.

Authors:  Martin Rakusa; Stefan J Cano; Bernadette Porter; Afsane Riazi; Alan J Thompson; Jeremy Chataway; Todd A Hardy
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

7.  Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.

Authors:  Karin Kannel; Kristi Alnek; Liina Vahter; Katrin Gross-Paju; Raivo Uibo; Kalle V Kisand
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

8.  How to run a multiple sclerosis relapse clinic.

Authors:  Emma C Tallantyre; Mark Wardle; Neil P Robertson
Journal:  Pract Neurol       Date:  2015-11-11

9.  Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study.

Authors:  Clotilde Nardin; Clotilde Latarche; Marc Soudant; Camille Dahan; Maud Michaud; Sophie Pittion-Vouyovitch; Francis Guillemin; Marc Debouverie; Guillaume Mathey
Journal:  PLoS One       Date:  2018-03-27       Impact factor: 3.240

10.  Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Authors:  Cristina Ramo-Tello; Yolanda Blanco; Luis Brieva; Bonaventura Casanova; Eva Martínez-Cáceres; Daniel Ontaneda; Lluís Ramió-Torrentá; Àlex Rovira
Journal:  J Pers Med       Date:  2021-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.